First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study

Abstract Introduction Renal cell carcinoma (RCC) is one of the most common types of urogenital cancer. The introduction of immune-based combinations, including dual immune-checkpoint inhibitors (ICI) or ICI plus tyrosine kinase inhibitors (TKIs), has radically changed the treatment landscape for met...

Full description

Saved in:
Bibliographic Details
Main Authors: Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, Linda Cerbone, Ondrej Fiala, Giuseppe Fornarini, Fernando Sabino Marques Monteiro, Carlo Cattrini, Johannes Landmesser, Carlo Messina, Anca Zgura, Sara Elena Rebuzzi, Andrey Soares, Francesco Carrozza, Jawaher Ansari, Francesco Grillone, Zsófia Küronya, Lorena Incorvaia, Dipen Bhuva, Cinzia Ortega, Cecilia Nasso, Ravindran Kanesvaran, Ilaria Zampiva, Camillo Porta, Sebastiano Buti, Matteo Santoni
Format: Article
Language:English
Published: Springer 2025-01-01
Series:Cancer Immunology, Immunotherapy
Subjects:
ARON-1 study
Good favorable-risk IMDC criteria
Immunotherapy
Immune-based combinations
Renal cell carcinoma
Online Access:https://doi.org/10.1007/s00262-024-03897-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-024-03897-x

Similar Items